Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.90
Bid: 3.60
Ask: 3.84
Change: -0.09 (-2.36%)
Spread: 0.24 (6.667%)
Open: 3.60
High: 3.90
Low: 3.60
Prev. Close: 3.81
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Plant Health Care and Wilbur-Ellis sign Agreement

9 Nov 2020 07:00

RNS Number : 5671E
Plant Health Care PLC
09 November 2020
 

 

RNS

 

 

 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

Plant Health Care® and Wilbur-Ellis® Agribusiness enter into Joint-Development Agreement for PREtec products

 

November 9, 2020 - Plant Health Care®, a leading provider of novel patent-protected biological products to global agriculture markets and Wilbur-Ellis® Agribusiness, a recognized leader in precision agriculture, crop protection, seed, nutrition and biological products, announced today they have entered a strategic collaboration for the development of products selected from Plant Health Care's PREtec peptide portfolio.

 

Plant Health Care's plant response elicitor ("PREtec") peptides represent a novel class of technology that stimulate the plant to defend itself. Derived from natural proteins, PREtec is an environmentally friendly approach to protecting crops and increasing yields and is compatible with mainstream agricultural practice. PREtec peptides promote plant health, suppress disease and soil nematodes and increase yield. PREtec may allow farmers to reduce applications of less safe chemical fungicides and achieve better control of damaging plant diseases.

 

Highlights:

 

- Plant Health Care has been developing PHC279 and other peptides that offer substantial benefits to growers in the U.S.

- Wilbur-Ellis, one of the largest U.S. ag retailers, will use its decades of agriculture knowledge and work with Plant Health Care to develop and launch products using PREtec peptides in the specialty crop market.

- Multiple PREtec products are being evaluated by the two companies.

- The first product launches will occur soon after regulatory approvals have been obtained.

 

Wilbur-Ellis, which has an established track record of bringing novel technologies to U.S. growers of specialty crops (fruits, nuts and vegetables), has been working with PREtec over the last growing season to understand how the technology works and where to best position it in the market. Based on that experience, they wish to accelerate their work with Plant Health Care to bring the benefits of these products to U.S. growers. This is intended to be a long-term collaboration to develop a series of products based on PREtec peptides.

 

Multiple PREtec products are being evaluated, initially focusing on improving disease and nematode control, and stress tolerance. The parties are committed to rapidly moving new products through the development process in order to make this novel technology available to growers as soon as possible. This collaboration brings together the development and marketing strengths, as well as decades of agriculture knowledge of Wilbur-Ellis, especially in biological products, with Plant Health Care's industry-leading expertise on PREtec peptides.

 

Chris Richards, CEO of Plant Health Care, said "We are delighted to be working with Wilbur-Ellis to bring the benefits of PREtec peptides to growers of specialty crops. Wilbur-Ellis has been working with our Employ brand (Harpin αβ) for many years and has significantly increased sales since being appointed exclusive distributor for U.S. specialty crops in 2019. They are the ideal partner for us to work with to develop a series of PREtec products in U.S. specialty crops over the coming years, with the first launch as early as the end of 2022, subject to regulatory approvals. This agreement represents an important validation of the commercial value of PREtec as we move to the first product launches. After more than six years and over $20m invested, the benefits of PREtec peptide products will soon be widely available to growers in the U.S. and elsewhere."

 

"Our mission is to maximize the return on investment for our customers," said Wilbur-Ellis Agribusiness President Mark Ripato. "We're looking at numerous paths to deliver those results. We believe the biologicals segment is one of those. Therefore, we are excited to work with Plant Health Care, a globally recognized innovator in this segment, to help us deliver value to the grower in a sustainable way."

 

# # #

About the Wilbur-Ellis Companies 

Founded in 1921, the Wilbur-Ellis companies are leading international marketers and distributors of agricultural products, animal feed, industrial chemicals, specialty chemicals and ingredients. By developing strong relationships, making strategic market investments and capitalizing on new opportunities, the Wilbur-Ellis companies have continued to grow the business with sales now over $3.4 billion. www.wilburellis.com

Wilbur-Ellis' Agribusiness generates more than $2 billion in sales revenue annually and has 160 branch locations throughout the U.S. www.wilburellisagribusiness.com

About Plant Health Care

Plant Health Care offers products to improve the health, vigor and yield of major field crops such as corn, soybeans, potatoes and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favorable environmental profile. Company website: www.planthealthcare.com

 

For further information from Plant Health Care plc, please contact:

Chris Richards, CEO Tel: +1 919 926 1600

Arden Partners plc - Nomad & Broker

John Llewellyn-Lloyd / Ben Cryer Tel: +44 (0) 20 7614 5900

 

For further information from Wilbur-Ellis, please contact:

Katherine Fordon, email: Katherine Fordon, (415) 722-4036.

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRZZMGMKVNGGZM
Date   Source Headline
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.